JP2023521228A5 - - Google Patents

Info

Publication number
JP2023521228A5
JP2023521228A5 JP2022562595A JP2022562595A JP2023521228A5 JP 2023521228 A5 JP2023521228 A5 JP 2023521228A5 JP 2022562595 A JP2022562595 A JP 2022562595A JP 2022562595 A JP2022562595 A JP 2022562595A JP 2023521228 A5 JP2023521228 A5 JP 2023521228A5
Authority
JP
Japan
Prior art keywords
seq
binding protein
amino acid
acid sequence
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562595A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521228A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/059377 external-priority patent/WO2021209357A1/en
Publication of JP2023521228A publication Critical patent/JP2023521228A/ja
Publication of JP2023521228A5 publication Critical patent/JP2023521228A5/ja
Pending legal-status Critical Current

Links

JP2022562595A 2020-04-14 2021-04-12 癌の併用療法 Pending JP2023521228A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063009555P 2020-04-14 2020-04-14
US63/009,555 2020-04-14
US202063110094P 2020-11-05 2020-11-05
US63/110,094 2020-11-05
PCT/EP2021/059377 WO2021209357A1 (en) 2020-04-14 2021-04-12 Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies

Publications (2)

Publication Number Publication Date
JP2023521228A JP2023521228A (ja) 2023-05-23
JP2023521228A5 true JP2023521228A5 (cg-RX-API-DMAC7.html) 2024-04-23

Family

ID=75497924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562595A Pending JP2023521228A (ja) 2020-04-14 2021-04-12 癌の併用療法

Country Status (7)

Country Link
US (1) US20230140694A1 (cg-RX-API-DMAC7.html)
EP (1) EP4136113A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023521228A (cg-RX-API-DMAC7.html)
CN (1) CN115698075A (cg-RX-API-DMAC7.html)
AU (1) AU2021256652A1 (cg-RX-API-DMAC7.html)
CA (1) CA3171557A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021209357A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
CN120752053A (zh) * 2023-03-03 2025-10-03 正大天晴药业集团南京顺欣制药有限公司 含抗tim-3抗体的药物组合

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
BRPI0811466A2 (pt) 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
AU2009290543B2 (en) 2008-09-12 2015-09-03 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
CN101898945B (zh) 2010-07-27 2013-05-08 大连理工大学 盐析萃取发酵液中丙酮和丁醇的方法
KR102023661B1 (ko) 2011-03-31 2019-09-23 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Icos에 대한 항체 및 이의 용도
ES2684552T3 (es) 2012-09-03 2018-10-03 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos dirigidos contra ICOS para tratar la enfermedad de injerto contra hospedador
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
MA53297A (fr) 2015-03-23 2022-05-04 Jounce Therapeutics Inc Anticorps anti-icos
PL3277321T3 (pl) * 2015-04-01 2024-11-18 Anaptysbio, Inc. Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
EP3494140A1 (en) * 2016-08-04 2019-06-12 GlaxoSmithKline Intellectual Property Development Ltd Anti-icos and anti-pd-1 antibody combination therapy
HRP20251424T1 (hr) * 2016-08-30 2025-12-19 Xencor, Inc. Bispecifična imunomodulacijska protutijela koja se vežu na kostimulacijske receptore i receptore imunosnih kontrolnih točaka
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3559041A1 (en) * 2016-12-20 2019-10-30 Kymab Limited Multispecific antibody with combination therapy for immuno-oncology
AU2018205401B2 (en) 2017-01-09 2025-01-02 Tesaro, Inc. Methods of treating cancer with anti-TIM-3 antibodies
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
TWI791519B (zh) * 2017-04-27 2023-02-11 美商提薩羅有限公司 針對淋巴細胞活化基因-3(lag-3)之抗體藥劑及其用途
JP2020522555A (ja) * 2017-06-09 2020-07-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 組み合わせ療法
TWI852940B (zh) * 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法

Similar Documents

Publication Publication Date Title
CN113924318B (zh) 具有抗BCMA抗体和gamma分泌酶抑制剂的联合疗法
US11168144B2 (en) Activatable anti-PDL1 antibodies, and methods of use thereof
JP7844558B2 (ja) リンパ球における阻害経路の中和
JP6767362B2 (ja) リンパ球における阻害経路の中和
CN106999594B (zh) 用于治疗瘤形成的治疗组合
CN110799543A (zh) 肝细胞癌的免疫治疗
WO2016154047A2 (en) Monoclonal antigen-binding proteins to intracellular oncogene products
CN115916247A (zh) 人tigit特异性单域抗体及其应用
US10752688B2 (en) Anti-human TIM-3 antibodies and methods of use thereof
CN107614530A (zh) 用于多发性骨髓瘤(mm)的治疗
EP3092252A1 (en) ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
JP2023521227A5 (cg-RX-API-DMAC7.html)
WO2020169698A1 (en) Sensitization of cancer cells to tnf by bet inhibition
JP2021530428A (ja) 頭頸部癌の処置
WO2023143315A1 (zh) 一种靶向ror1的抗体或其抗原结合片段及其应用
WO2022150642A1 (en) Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
WO2022179466A1 (zh) 抗Siglec15抗体及其用途
CN120344271A (zh) 抗her2抗体药物偶联物治疗乳腺癌
CN115698075A (zh) 涉及抗icos和抗pd1抗体,任选地进一步涉及抗tim3抗体的癌症的组合治疗
TW202005983A (zh) 抗-人類pd-l1之抗體及其用途
KR20210019487A (ko) 스트레스 관련 장애 및 암의 치료를 위한 물질 및 방법
CA3212604A1 (en) Methods for treating cancer with anti-ilt3 antibodies
JP2025069950A (ja) Api5タンパク質に特異的に結合する抗体
JP2025519980A (ja) Pd-1阻害剤またはpd-l1阻害剤およびクローディン18.2を標的にする抗体-薬物コンジュゲートによるがん処置
US20230192833A1 (en) New anti-VEGFC antibodies and uses thereof